Destiny Pharma plc – Notice of R&D Update Meeting
Brighton, United Kingdom – 22 September 2022 – Destiny Pharma plc (AIM:DEST), a clinical … Continue reading “Destiny Pharma plc – Notice of R&D Update Meeting”
Brighton, United Kingdom – 22 September 2022 – Destiny Pharma plc (AIM:DEST), a clinical … Continue reading “Destiny Pharma plc – Notice of R&D Update Meeting”
Denmark’s first fully functional generally applicable quantum computer will be available in … Continue reading “Novo Nordisk Foundation: Major investment for developing Denmark’s first fully functional quantum computer”
BioInnovation Institute (BII) announces that it has entered a collaboration with Imperial … Continue reading “World-class translational project enters the Bio Studio program as part of collaboration with Imperial College London”
BERLIN, 15 September 2022 – Ariceum Therapeutics (Ariceum), a private biotech company developing … Continue reading “Ariceum Therapeutics Q4 2022 Investor and Scientific Conference”
AMSTERDAM, NETHERLANDS – 15th September 2022 — Synaffix B.V., a biotechnology company focused … Continue reading “Synaffix Wins ‘Best ADC Platform Technology’ Award Again at World ADC Awards Ceremony 2022”
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative … Continue reading “Futura Medical Interim Results for the Six Months ended 30 June 2022”
STORM recognised as an innovative early-stage biotechnology company pioneering novel drug targets … Continue reading “Fierce Biotech names STORM Therapeutics as one of its “Fierce 15” Biotech Companies of 2022”
alfapump® – strong interim data / on track to report primary endpoint … Continue reading “Sequana Medical announces H1 2022 results and provides business update”
The Pedro J. Romero Award recognizes individuals who have made outstanding contributions … Continue reading “Professor Melief to receive 2022 SITC Pedro J. Romero Award”
7 September 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering … Continue reading “STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer”
Synaffix to provide access to proprietary ADC technologies (GlycoConnect™, HydraSpace™ and exatecan-based … Continue reading “Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal”
BioInnovation Institute (BII), an international commercial non-profit foundation incubating and accelerating world-class … Continue reading “BII announces new cohort of companies entering the Venture Lab program”
• Abstracts demonstrate efficacy of combination antibiotics with STIMULAN beads compared to … Continue reading “Biocomposites to present latest STIMULAN® data at the European Bone and Joint Infection Society Annual Meeting”
Dublin, Ireland, 31 August 2022: SynOx Therapeutics Limited (“SynOx” or the “Company”), the … Continue reading “Emactuzumab designated as an Orphan Medicinal Product in Europe”
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of … Continue reading “Highly positive FM71 Phase 3 Study Results with all primary and secondary endpoints achieved, MED3000 remains on track to obtain US FDA marketing authorisation”
BANGALORE, INDIA – FOSTER CITY, USA – SINGAPORE – 30 August 2022 – … Continue reading “Novo Holdings leads US$50M investment in South Asia–based MedGenome”
Bactolife today announced that the Bill & Melinda Gates Foundation has committed, … Continue reading “Novo Holdings portfolio company Bactolife receives new funding to advance lifesaving protein technology”
Ghent, Belgium – 25 August 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or … Continue reading “Alexandra Clyde appointed to Sequana Medical Board of Directors”
LONDON and RALEIGH, N.C., Aug. 24, 2022 (GLOBE NEWSWIRE) — Verona Pharma … Continue reading “Verona Pharma strengthens commercialization leadership team”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2022 Optimum Strategic Communications All rights reserved.
The Spice Building
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
